Albany Molecular Research Inc. (AMRI) is seeking a partner for its glycine transporter-1 (GlyT-1) inhibitor research and development program. AMRI’s lead series is positively differentiated from advanced clinical compounds through a preferred competitive inhibition mode of action and higher potency.
The GlyT-1 program is in the advanced lead optimization phase, close to confirming identification of a pre-clinical candidate. AMRI has developed the lead series and backup series of GlyT-1 inhibitors to optimize the drug-like characteristics for advancement into preclinical development. In preclinical studies, these compounds show excellent potency in animal efficacy models and selectivity without the side-effect profile of traditional anti-psychotic medications.